Circulating Tumor Cell (CTC) Market Size & Growth | Report 2028

Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Methods, and CTC Analysis), Application (Clinical/Liquid Biopsy and Research), and End User (Hospital and Clinics, Research and Academic Institutes, and Diagnostic Centers)

  • Report Code : TIPRE00026639
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 194

Circulating Tumor Cell (CTC) Market Size & Growth | Report 2028

Buy Now

The circulating tumor cell (CTC) diagnostics market is projected to reach US$ 3,656.38 million by 2028 from US$ 1,909.41 million in 2021; it is estimated to grow at a CAGR of 9.7% from 2021 to 2028.

Circulating tumor cells (CTCs) have tremendous potential in diagnosing and treating cancer. Many techniques have been developed and are under continuous improvement to enhance their efficacy of CTC detection, isolation, enrichment, and analysis. Mostly used approach for CTC detection and isolation is immune-based detection, whereby antibodies selectively bind cell surface antigens. Tumor cells express different cell surface markers than blood cells and are separated from the circulatory cells. CTCs help detect minor subgroups of cells present in the primary tissue, which might eventually cause treatment resistance or relapse of the disease. Hence, detecting and characterizing CTCs can become an inevitable step in treating solid tumor malignancies.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Circulating Tumor Cell (CTC) Diagnostics Market: Strategic Insights

Circulating Tumor Cell (CTC) Diagnostics Market
  • CAGR
    CAGR (2021 - 2028)
    9.7%
  • Market Size 2021
    US$ 1.91 Billion
  • Market Size 2028
    US$ 3.66 Billion

Market Dynamics

GROWTH DRIVERS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
FUTURE TRENDS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
OPPORTUNITIES
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX

Key Players

  • Thermo Fisher Scientific Inc
  • STEMCELL Technologies Inc
  • QIAGEN
  • Precision Medicine Group LLC
  • Advanced Cell Diagnostics Inc BIO TECHNE CORPORATION
  • Epic Sciences
  • ScreenCell
  • Ikonisys Inc
  • IVDiagnostics

Regional Overview

Regional Overview
  • North America
  • Europe
  • Asia-Pacific
  • South and Central America
  • Middle East and Africa

Market Segmentation

Market SegmentTechnology
  • CTC Detection and Enrichment Method
  • CTC Direct Detection Methods
  • CTC Analysis
Market SegmentApplication
  • Clinical/Liquid Biopsy and Research
Market SegmentEnd User
  • Hospital and Clinics
  • Research and Academic Institutes
  • Diagnostic Centers
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.


The circulating tumor cell (CTC) diagnostics market is segmented on the basis of technology, application, end-user, and geography. The market, by geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The report offers insights and in-depth analysis of the market, emphasizing parameters such as market trends, technological advancements, and market dynamics, along with the analysis of the competitive landscape of the globally leading market players. 

Market Insights

Rising Demand for Minimally Invasive Diagnostic Procedures to Drive Circulating Tumor Cell (CTC) Diagnostics Market Growth during Forecast Period

There is a growing preference for minimally invasive or noninvasive procedures among patients for diagnostic purposes. Early cancer detection, mutation detection, tumor monitoring throughout treatment, and recurrence monitoring are possible using circulating tumor cell diagnostics, which uses a noninvasive method. Researchers can trace all epigenetic and genetic changes in solid tumors using blood samples with circulating tumor cells. Patients are at a lesser risk with these tests, and clinicians can readily perform them multiple times. Patients prefer minimally invasive procedures because the advanced instruments used in such procedures allow for more delicate and complex work to be performed with lower risk, less pain, and less scarring.

Due to technological advancements in feasibility and processing times, circulating tumor cell diagnostics and liquid biopsy have recently attracted considerable interest as a noninvasive alternative to tissue biopsy in cancer patients. Liquid biopsy adoption will be aided by an increased understanding of improved minimally invasive cancer detection technologies. The market growth will be influenced by rising demand for noninvasive tools and laboratory acceptance of CTCs tests and liquid biopsy. A liquid biopsy is a noninvasive and simple alternative to surgical biopsies that allows doctors to discover a range of information about tumors from a simple blood sample. Blood tests are painless, noninvasive, bear no risks, and cut down the cost and time to diagnose a problem. In addition, CTCs, cfDNAs, exosomes, and microvesicles can be detected in a blood sample, making blood-based liquid biopsies more popular. Thus, the increased demand for minimally invasive diagnostic tests is spurring the market growth. 

Technology Insights               

Based on technology, the global circulating tumor cell (CTC) diagnostics market is segmented into CTC detection and enrichment method, CTC direct detection methods, and CTC analysis. In 2020, the CTC detection and enrichment segment held the largest share of the market. Moreover, the same segment is expected to register the highest CAGR in the market during 2021–2028. With the help of CTC diagnostics, individuals can be diagnosed early. Therefore, the adaption of these technologies is increasing, which is expected to drive the market during the forecast period.   

Application Insights

Based on application, the global circulating tumor cell (CTC) diagnostics market is bifurcated into clinical/liquid biopsy and research. In 2020, the research segment held a larger share of the market and the same segment is expected to register a higher CAGR in the market during 2021–2028. Owing to the rise in the detection and diagnosis of various medical conditions across the globe, the market is expected to grow in the future.

End-User Insights

Based on end-users, the circulating tumor cell (CTC) diagnostics market is segmented into hospital and clinics, research and academic institutes, and diagnostic centers. The research and academic institutes segment held the largest market share in 2021 and is expected to register the highest CAGR in the market during the forecast period. The increasing research on cancer diagnosis and therapeutic development, growing awareness related to cancer diagnosis, and high investment from government and other enterprises are a few of the critical factors supporting the market growth for the Research and Academic Institutes segment.  

 

Product launches, and mergers and acquisitions are highly adopted strategies by the global circulating tumor cell (CTC) diagnostics market players. A few of the recent key market developments are listed below:

  • In January 2022, Thermo Fisher Scientific Inc. announced the complete acquisition of PeproTech for a total cash purchase price of approx. US$ 1.85 billion.
  • In December 2021, Epic Sciences, Inc. announced the launch of DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw.

The COVID-19 pandemic had a negative impact on the people suffering from cancer and cancer surveillance capacities. Also, due to the pandemic, reduced resources and availability to care made cancer detection and treatment difficult, resulting in higher mortality, and lower survival. Due to a compromised immune system caused by cancer and/or its treatment, cancer patients are susceptible to infectious pathogens (e.g., surgery and chemotherapy). This has raised fears that COVID-19 problems and mortality may be common in cancer patients. Thus, the pandemic negatively impacts the circulating tumor cell (CTC) diagnostics market.

Circulating Tumor Cell (CTC) Diagnostics Market Report Scope

Report Attribute Details
Market size in 2021 US$ 1.91 Billion
Market Size by 2028 US$ 3.66 Billion
Global CAGR (2021 - 2028) 9.7%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Technology
  • CTC Detection and Enrichment Method
  • CTC Direct Detection Methods
  • CTC Analysis
By Application
  • Clinical/Liquid Biopsy and Research
By End User
  • Hospital and Clinics
  • Research and Academic Institutes
  • Diagnostic Centers
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Thermo Fisher Scientific Inc
  • STEMCELL Technologies Inc
  • QIAGEN
  • Precision Medicine Group LLC
  • Advanced Cell Diagnostics Inc BIO TECHNE CORPORATION
  • Epic Sciences
  • ScreenCell
  • Ikonisys Inc
  • IVDiagnostics
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Circulating Tumor Cell (CTC) Diagnostics Market Segmentation

The global circulating tumor cell (CTC) diagnostics market is segmented on the basis of technology, application, end-user, and geography. In terms of technology, the market is segmented into CTC detection and enrichment method, CTC direct detection methods, and CTC analysis. Based on application, the global circulating tumor cell (CTC) diagnostics market is bifurcated into clinical/liquid biopsy and research. Based on end-users, the circulating tumor cell (CTC) diagnostics market is segmented into hospital and clinics, research and academic institutes, and diagnostic centers. The market, by geography, is broadly segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South and Central America.

Company Profiles

  • Thermo Fisher Scientific Inc.
  • STEMCELL Technologies Inc.
  • QIAGEN
  • Precision Medicine Group, LLC.
  • Advanced Cell Diagnostics, Inc. (BIO-TECHNE CORPORATION)
  • Epic Sciences
  • ScreenCell
  • Ikonisys, Inc.
  • IVDiagnostics
  • Fluxion Biosciences Inc0
Report Coverage

Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered

Segment Covered

Technology, Application, and End User

Regional Scope

Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope

Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions


What is circulating tumor cell (CTC) diagnostics?

A Circulating Tumor Cell (CTC) is a cell that shed into lymphatics from the primary tumor and carried out throughout the body with blood circulation. Circulating tumor cells are the seeds for growth and metastases for additional tumors in distant organs and is responsible for majority of cancer related deaths. The diagnosis, detection and analysis of CTC can assist in patients’ prognoses determine appropriate tailored treatments for the patients. The CTC diagnosis has a lot of advantages for traditional diagnostic procedures. The advantages of CTC detection include, it is non-invasive, effective and can be used repeatedly. The CTC detection and enrichment, CTC direct detection and CTC analysis are the technologies used for CTC detection.

What are the driving factors for the circulating tumor cell (CTC) diagnostics market across the globe?

Key factors that are driving the growth of this market are increasing prevalence of cancer across the globe along with rising demand for minimally invasive diagnostic procedures.

Which Technology led the circulating tumor cell (CTC) diagnostics market?

The CTC detection and enrichment method segment dominated the global circulating tumor cell (CTC) diagnostics market and held the largest revenue share of 62.85% in 2021.

Which application held the largest share in the circulating tumor cell (CTC) diagnostics market?

The research segment dominated the global circulating tumor cell (CTC) diagnostics market and accounted for the largest revenue share of 67.65% in 2021.

What is the regional market scenario of sleep apnea diagnostics?

Global circulating tumor cell (CTC) diagnostics market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. In North America, the U.S. is the largest market for sleep apnea diagnostics. The market growth in the country is attributed to the factors such as most foreign companies in the healthcare sector have R&D centres in the United States. Moreover, the increase in prevalence of cancer in the country along with various organic and inorganic developments done by the companies. And, Asia Pacific is the fastest-growing region growing at the CAGR of 10.3% during the forecast period.

Who are the key players in the circulating tumor cell (CTC) diagnostics market?

The circulating tumor cell (CTC) diagnostics market majorly consists of the players such as Thermo Fisher Scientific, Stemcell Technologies, Inc, QIAGEN, Precision Medicine Group, LLC, Advanced Cell Diagnostics (Bio-Techne Corporation), Epic Lifesciences, Screencell, Ikonisys, Inc, IV Diagnostics, Fluxion Biosciences, among others

The List of Companies - Circulating Tumor Cell (CTC) Diagnostics Market

  1. Thermo Fisher Scientific Inc.
  2. STEMCELL Technologies Inc.
  3. QIAGEN
  4. Precision Medicine Group, LLC.
  5. Advanced Cell Diagnostics, Inc. (BIO-TECHNE CORPORATION)
  6. Epic Sciences
  7. ScreenCell
  8. Ikonisys, Inc.
  9. IVDiagnostics
  10. Fluxion Biosciences Inc.

Trends and growth analysis reports related to Biotechnology : READ MORE..